Affiliated Genetics, Inc.

After 23 years of operations providing DNA testing applications, genomic services, and DNA-based, human identity testing, Affiliated Genetics has closed.

Related News

ANCIENT SUBMERGED CYPRESS FOREST COULD HOLD POTENTIAL FOR NEW MEDICINES, BIOTECHNOLOGY

IFLScience | April 09, 2020

news image

A 60,000-year-old forest submerged in the Gulf of Mexico may hold potential for the development of new medicines and biotechnology in the future – and scientists are only just beginning to understand what other secrets it may hold. Along the banks of a river in Alabama was once a flourishing bald cypress forest. As the trees grew and died, they eventually fell and become buried in peat and sediment. Over time, sea levels rose and covered the ancient forest far beneath the surface of the oc...

Read More

BIOMARIN EXTENDS GENE THERAPY LEADERSHIP WITH DINAQOR IN A PRECLINICAL COLLABORATION & LICENSE AGREEMENT

BioMarin | May 03, 2020

news image

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales. The company did not ...

Read More

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne | August 04, 2020

news image

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More

MEDTECH

TO SEARCH FOR NEW TREATMENTS DISEASES, UW OSHKOSH PARTNERED WITH FAUNA BIO

Fauna Bio | April 01, 2022

news image

A biotechnology business pioneering comparative, computational, and translational genomics, Fauna Bio, announced collaboration with the University of Wisconsin OshKosh to speed the translation of human treatments identified via research into extreme mammal adaption. Fauna Bio's sponsorship of UW Oshkosh with $500,000 expands the University's capability for biomedical partnerships and helps promote the University as a destination for academics exploring innovative animal models and ...

Read More
news image

ANCIENT SUBMERGED CYPRESS FOREST COULD HOLD POTENTIAL FOR NEW MEDICINES, BIOTECHNOLOGY

IFLScience | April 09, 2020

A 60,000-year-old forest submerged in the Gulf of Mexico may hold potential for the development of new medicines and biotechnology in the future – and scientists are only just beginning to understand what other secrets it may hold. Along the banks of a river in Alabama was once a flourishing bald cypress forest. As the trees grew and died, they eventually fell and become buried in peat and sediment. Over time, sea levels rose and covered the ancient forest far beneath the surface of the oc...

Read More
news image

BIOMARIN EXTENDS GENE THERAPY LEADERSHIP WITH DINAQOR IN A PRECLINICAL COLLABORATION & LICENSE AGREEMENT

BioMarin | May 03, 2020

BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the company has entered into a preclinical collaboration and license agreement with DiNAQOR AG (DiNAQOR), a gene therapy platform company, to develop novel gene therapies to treat rare genetic cardiomyopathies. DiNAQOR will receive an undisclosed upfront payment and is eligible to receive development, regulatory and commercial milestones on product sales in addition to tiered royalties on worldwide sales. The company did not ...

Read More
news image

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne | August 04, 2020

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More
news image

MEDTECH

TO SEARCH FOR NEW TREATMENTS DISEASES, UW OSHKOSH PARTNERED WITH FAUNA BIO

Fauna Bio | April 01, 2022

A biotechnology business pioneering comparative, computational, and translational genomics, Fauna Bio, announced collaboration with the University of Wisconsin OshKosh to speed the translation of human treatments identified via research into extreme mammal adaption. Fauna Bio's sponsorship of UW Oshkosh with $500,000 expands the University's capability for biomedical partnerships and helps promote the University as a destination for academics exploring innovative animal models and ...

Read More